Phase
Condition
Gastric Cancer
Breast Cancer
Head And Neck Cancer
Treatment
ipilimumab +pembrolizumab +durvalumab
Clinical Study ID
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Cytohistological confirmation is required for diagnosis of cancer.
Signed informed consent before recruiting.
Age above 18 years with estimated survival over 3 months.
Child-Pugh class A or B/Child score > 7; ECOG score < 2
Tolerable coagulation function or reversible coagulation disorders
Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L;Hb≥90g/L; PLT ≥50×10E9/L;INR < 2.3 or PT < 6 seconds above control;Cr ≤ 145.5umul/L;Albumin > 28 g/L;Total bilirubin < 51 μmol/L
At least one tumor lesion meeting measurable disease criteria as determined byRECIST v1.1.
Birth control.
Willing and able to comply with scheduled visits, treatment plan and laboratorytests.
Exclusion
Exclusion Criteria:
Patients participated in clinical trials of equipment or drugs (signed informedconsent) within 4 weeks;
Patients accompany by ascites, hepatic encephalopathy and esophageal and gastricvarices bleeding;
Any serious accompanying disease, which is expected to have an unknown, impact onthe prognosis, include heart disease, inadequately controlled diabetes andpsychiatric disorders;
Patients accompanied with other tumors or past medical history of malignancy;
Pregnant or lactating patients, all patients participating in this trial must adoptappropriate birth control measures during treatment;
Patients have poor compliance. Any contraindications for hepatic arterial infusion procedure: A.Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%). B.Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C.Knownsevere atheromatosis. D.Known uncontrolled blood hypertension (> 160/100 mm/Hg).
Allergic to contrast agent;
Any agents which could affect the absorption or pharmacokinetics of the study drugs
Other conditions that investigator decides not suitable for the trial.
Study Design
Study Description
Connect with a study center
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong 510260
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.